Novel Vesicular Bilosomal Delivery Systems for Dermal/Transdermal Applications
- PMID: 37424346
- DOI: 10.2174/1567201820666230707161206
Novel Vesicular Bilosomal Delivery Systems for Dermal/Transdermal Applications
Abstract
The application of therapeutically active molecules through the dermal/transdermal route into the skin has evolved as an attractive formulation strategy in comparison to oral delivery systems for the treatment of various disease conditions. However, the delivery of drugs across the skin is limited due to poor permeability. Dermal/transdermal delivery is associated with ease of accessibility, enhanced safety, better patient compliance, and reduced variability in plasma drug concentrations. It has the ability to bypass the first-pass metabolism, which ultimately results in steady and sustained drug levels in the systemic circulation. Vesicular drug delivery systems, including bilosomes, have gained significant interest due to their colloidal nature, improved drug solubility, absorption, and bioavailability with prolonged circulation time for a large number of new drug molecules. Bilosomes are novel lipid vesicular nanocarriers comprising bile salts, such as deoxycholic acid, sodium cholate, deoxycholate, taurocholate, glycocholate or sorbitan tristearate. These bilosomes are associated with high flexibility, deformability, and elasticity attributed to their bile acid component. These carriers are advantageous in terms of improved skin permeation, increased dermal and epidermal drug concentration, and enhanced local action with reduced systemic absorption of the drug, resulting in reduced side effects. The present article provides a comprehensive overview of the biopharmaceutical aspects of dermal/transdermal bilosome delivery systems, their composition, formulation techniques, characterization methods, and applications.
Keywords: Bilosomes; bile salts; dermal.; liposomes; transdermal; vesicular carriers.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Dermal drug delivery via bilosomes: a synergistic integration for better therapeutic outcomes.J Microencapsul. 2024 Dec;41(8):818-831. doi: 10.1080/02652048.2024.2423618. Epub 2024 Nov 7. J Microencapsul. 2024. PMID: 39508079 Review.
-
Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam.Int J Pharm. 2015 May 15;485(1-2):329-40. doi: 10.1016/j.ijpharm.2015.03.033. Epub 2015 Mar 18. Int J Pharm. 2015. PMID: 25796122
-
Lipid vesicles: A versatile drug delivery platform for dermal and transdermal applications.Colloids Surf B Biointerfaces. 2020 Nov;195:111262. doi: 10.1016/j.colsurfb.2020.111262. Epub 2020 Jul 17. Colloids Surf B Biointerfaces. 2020. PMID: 32736123 Review.
-
Brij® integrated bilosomes for improving the transdermal delivery of niflumic acid for effective treatment of osteoarthritis: In vitro characterization, ex vivo permeability assessment, and in vivo study.Int J Pharm. 2023 Jun 10;640:123024. doi: 10.1016/j.ijpharm.2023.123024. Epub 2023 May 6. Int J Pharm. 2023. PMID: 37156309
-
Bilosomes as a novel ocular drug delivery system: Assessing the material attributes, process parameters, and quality attributes.Exp Eye Res. 2025 Jun;255:110364. doi: 10.1016/j.exer.2025.110364. Epub 2025 Mar 27. Exp Eye Res. 2025. PMID: 40157630 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources